TABLE 2.
The association of m6A, m5C, and m1A methylation in HCC.
| Modification type | Regulators | Expression | Clinical characters | Function in HCC | Target | PMID |
|---|---|---|---|---|---|---|
| m6A | ALKBH5 | Down | Favorable prognosis | Inhibit proliferation and invasion | LYPD1 | 32,772,918 |
| m6A | METTL3 | Up | Poor prognosis | Promote vascular invasion, and metastasis | HBXIP | 33,305,825 |
| m6A | YTHDF3 | Up | Poor prognosis | promote invasion, migration, and EMT | Zeb1 | 32,653,519 |
| m6A | METTL14 | Down | Favorable prognosis | Inhibit invasion, migration, and EMT | EGFR/PI3K/Akt | 33,380,825 |
| m6A | YTHDF1 | Up | Poor prognosis | Promote proliferation, migration, and invasion | PI3K/Akt/mTOR | 34,088,349 |
| m6A | FTO | Up | Poor prognosis | Promote initiation, metastasis, and chemoresistance | AMD1 | 33,783,988 |
| m5C | NSUN2 | Up | Poor prognosis and advanced TNM stage | Promote metastasis | H19 | 32,978,516 |
| m5C | NSUN4 | Up | Poor prognosis | — | — | 32,269,723 |
| m5C | ALYREF | Up | Poor prognosis | — | — | 32,944,246 |
| m1A | TRMT6 | Up | Poor prognosis | — | PI3K/Akt | 32,934,298 |